ProMIS Neurosciences Inc. (ON) (PMN) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, ProMIS Neurosciences Inc. (ON) (NASDAQ: PMN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $3.00 (-9.37% 1D, market cap $29.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, PMN ranks #604 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PMN carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AARD (Aardvark Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $29.8M) and FLNA (Filana Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M). Among the 5-stock peer group, PMN leads on earnings multiple (N/A) while RMTI leads on capital efficiency (-10.6% ROIC).
Per PMN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001374339), ProMIS Neurosciences Inc. (ON) generated $112.5M in revenue (+138.7% YoY), -$39.7M in net income, and -$28.1M in free cash flow against $9.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 28.2 (OVERSOLD (<32))
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While PMN currently carries a cautious 35/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.80) and Max Pain ($3.15) forces dealer call-delta covering toward $28.77.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
ProMIS Neurosciences Inc. (ON) (PMN) dropped -9.37% to $3.00, trading at 2% of its 52-week range ($2.84 – $27.4). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday. Jin Medical
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity Therapeutics
The mean of analysts' price targets for Promis Neurosciences (PMN) points to a 293% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raisi
HCA's Q3 results could benefit from higher admissions, occupancy and inpatient revenues, but rising costs and fewer outpatient surgeries cloud the outlook.
Gainers Pomdoctor (NASDAQ:POM) stock moved upwards by 115.1% to $1.43 during Wednesday's regular session. The market value of their outstanding shares is at $4.9 million. Stablecoin Development (AMEX:SDEV) stock
Universal Health Services' Q3 revenues are expected to rise on higher patient admissions, but surging operating costs and wage pressures could weigh on earnings growth.
Roth Capital analyst Boobalan Pachaiyappan maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and lowers the price target from $29 to $15.
Nasdaq unusual-volume stocks on Nov. 3, 2026 included PARA up 101%, CENN down 86.15%, and other names trading above their 50-day average volume.
CI's Q3 revenues are poised to rise on pharmacy and premium growth, but declining Evernorth profits and higher medical costs could weigh on earnings.
Company to host investor conference call and webcast at 4:30 p.m. ET.Cambridge, Massachusetts, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +138.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PMN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PMN. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, ProMIS Neurosciences Inc. (ON) (PMN) ranks #604 by composite RQD confidence (35/100, grade D-) and #799 by equity capitalization ($29.7M). Within this direct 5-issuer industry benchmark cohort, PMN leads on earnings valuation at N/A trailing P/E, while RMTI leads on capital efficiency and profitability with -10.6% ROIC and 16.9% gross margin. FLNA currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with PMN at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PMN
ACTIVE
ProMIS Neurosciences Inc. (ON) | D- | 35/100 | — | — | -35.0% | -9.37% | $29.7M | Benchmark Subject |
| AARD Aardvark Therapeutics Inc. | E | 33/100 | — | — | -35.0% | -11.76% | $29.8M | /aard-vs-pmn → |
| FLNA Filana Therapeutics Inc. | D- | 38/100 | — | — | -35.0% | -9.81% | $30.0M | /flna-vs-pmn → |
| NXTC NextCure Inc. | D- | 37/100 | — | — | -35.0% | -9.75% | $28.9M | /nxtc-vs-pmn → |
| RMTI Rockwell Medical Inc. | E | 23/100 | — | 16.9% | -10.6% | -2.26% | $28.5M | /rmti-vs-pmn → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), ProMIS Neurosciences Inc. (ON) (PMN) reported GAAP revenue of $112.5M (+138.7% vs. FY2024 revenue of $47.1M , and +181.6% cumulative change since FY2023) , GAAP net income of -$39.7M, operating cash flow of -$28.1M, and free cash flow of -$28.1M (-3.4% YoY). On the balance sheet, PMN closed FY2025 with $9.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $112.5M | -$39.7M | -$28.1M | -$28.1M | $9.2M | — |
| FY2024 (FY) | 2024-12-31 | $47.1M | $2.8M | -$27.2M | -$27.2M | $18.9M | — |
| FY2023 (FY) | 2023-12-31 | $39.9M | -$13.2M | -$10.8M | -$10.8M | — | — |
As of 2026-11-03, ProMIS Neurosciences Inc. (ON) (NASDAQ: PMN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $3.00 (-9.37% 1D, market cap $29.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, PMN ranks #604 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PMN carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AARD (Aardvark Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $29.8M) and FLNA (Filana Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M). Among the 5-stock peer group, PMN leads on earnings multiple (N/A) while RMTI leads on capital efficiency (-10.6% ROIC).
Per PMN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001374339), ProMIS Neurosciences Inc. (ON) generated $112.5M in revenue (+138.7% YoY), -$39.7M in net income, and -$28.1M in free cash flow against $9.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
PMN last traded at $3.00 (-9.37% on volume of 3,536,154 shares), positioning the stock -72.22% below its 50-day simple moving average ($10.80) and -76.64% below its 200-day simple moving average ($12.84). Across its 52-week range of $2.84 to $27.40, PMN sits at the 0.7% percentile with a 14-day RSI of 28.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.62 to $3.38).
ProMIS Neurosciences Inc. (ON) (PMN) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $3.00 (-9.37% 1D, market capitalization $29.7M).
ProMIS Neurosciences Inc. (ON) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..1B. Reported revenue is — across the periods provided.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), ProMIS Neurosciences Inc. (ON) (PMN) reported $112.5M in annual revenue (up from $47.1M in FY2024, +138.7% YoY) and -$39.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($39.9M revenue, -$13.2M net income) through FY2025, PMN scaled operating cash flow to -$28.1M and free cash flow to -$28.1M, backed by $9.2M in total assets against $0 in total debt.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), PMN carries a macro regime beta of 1.00 and gross margin of —.
Real-time company headlines, analyst actions, and sector developments for ProMIS Neurosciences Inc. (ON) (PMN) • Click "Debate This Headline" to argue it in the Roar Pit below
Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday. Jin Medical
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity Therapeutics
The mean of analysts' price targets for Promis Neurosciences (PMN) points to a 293% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raisi
HCA's Q3 results could benefit from higher admissions, occupancy and inpatient revenues, but rising costs and fewer outpatient surgeries cloud the outlook.
Gainers Pomdoctor (NASDAQ:POM) stock moved upwards by 115.1% to $1.43 during Wednesday's regular session. The market value of their outstanding shares is at $4.9 million. Stablecoin Development (AMEX:SDEV) stock
Universal Health Services' Q3 revenues are expected to rise on higher patient admissions, but surging operating costs and wage pressures could weigh on earnings growth.
Roth Capital analyst Boobalan Pachaiyappan maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and lowers the price target from $29 to $15.
Nasdaq unusual-volume stocks on Nov. 3, 2026 included PARA up 101%, CENN down 86.15%, and other names trading above their 50-day average volume.
Don't sleep on PMN's setup in Health Care. Beta of 1.0 and a 52-week range of $10.24 - $12.68 show a tightly held price, with the stock trading near the top of that band at 11.08.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (35/100) backs up the fundamental quality.
Both sides have a point here — PMN's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
Sitting on the sidelines or leaning short PMN above $3.31. Operating income fell from -$14.3M in FY 2023 to -$40.2M in FY 2025 while cash dropped to $6.1M, leaving ROIC at -35% and FCF at -$28.1M.. Until Fundamental Cash Engine (8/20) and FCF yield (0.0%) inflect higher, upside is capped near $27.40.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: